uniQure (QURE) Cash from Investing Activities (2016 - 2026)
uniQure's (QURE) quarterly Cash from Investing Activities came in at $98.6 million in Q1 2026, up 390.37% year-on-year from $20.1 million in Q1 2025, and up 122.33% quarter-over-quarter from -$441.4 million in Q4 2025.
uniQure (QURE) Cash from Investing Activities (2016 - 2026) Analysis & Trends
uniQure's Cash from Investing Activities history runs 11 years deep, the most recent figure standing at $98.6 million for Q1 2026.
- On a quarterly basis, Cash from Investing Activities rose 390.37% year-over-year to $98.6 million in Q1 2026; TTM through Mar 2026 was -$243.2 million, a 304.19% decrease from a year earlier, with the FY2025 full-year figure at -$321.6 million, down 297.35% from the prior year.
- Cash from Investing Activities grew to $98.6 million in Q1 2026 per QURE's latest filing, from -$441.4 million in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $98.6 million in Q1 2026 and bottomed at -$441.4 million in Q4 2025.
- The 5-year median for Cash from Investing Activities is $20.1 million (2025), against an average of -$26.4 million.
- Across the five-year window, Cash from Investing Activities plunged 6103.16% in 2023 and surged 2041.4% in 2024, its largest moves.
- Year by year, Cash from Investing Activities stood at -$168.2 million in 2022, then soared by 135.41% to $59.6 million in 2023, then slumped by 144.7% to -$26.6 million in 2024, then plunged by 1557.79% to -$441.4 million in 2025, then surged by 122.33% to $98.6 million in 2026.
- Per Business Quant, the three latest QURE Cash from Investing Activities figures stand at $98.6 million (Q1 2026), -$441.4 million (Q4 2025), and $26.6 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | -45.51 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | -431.90 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -428.90 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 172.62 Mn |
| 10 | uniQure | 2.41 Bn | 2.41 Bn | 3.34 Mn | 98.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 98.56 Mn |
| Mar 31, 2026 | 98.56 Mn |
| Dec 31, 2025 | -441.37 Mn |
| Dec 31, 2025 | -441.37 Mn |
| Sep 30, 2025 | 26.58 Mn |
| Sep 30, 2025 | 26.58 Mn |
| Jun 30, 2025 | 73.07 Mn |
| Jun 30, 2025 | 73.07 Mn |
| Mar 31, 2025 | 20.10 Mn |
| Mar 31, 2025 | 20.10 Mn |
| Dec 31, 2024 | -26.62 Mn |
| Dec 31, 2024 | -26.62 Mn |
| Sep 30, 2024 | 47.67 Mn |
| Sep 30, 2024 | 47.67 Mn |
| Jun 30, 2024 | 77.94 Mn |
| Jun 30, 2024 | 77.94 Mn |
| Mar 31, 2024 | 63.99 Mn |
| Mar 31, 2024 | 63.99 Mn |
| Dec 31, 2023 | 59.56 Mn |
| Dec 31, 2023 | 59.56 Mn |